

CURRICULUM VITAE

Fotini B. Karassa, MD, PhD

Lecturer of Rheumatology

Department of Medicine, School of Health Sciences,

University of Ioannina

Ioannina, Greece

September 2024

BIOGRAPHICAL INFORMATION

NAME: Fotini B. Karassa, MD, PhD

PRESENT ADDRESS: 6 Tharypa Street, 45221, Ioannina, Greece

CITIZENSHIPS: Greece (EU)

DEGREES: M.D., University of Ioannina, School of Medicine¹, Ioannina, Greece, 1988

Ph.D., University of Athens, School of Medicine, Athens, Greece. Magna cum laude, 2000

CURRENT POSITION: Lecturer of Rheumatology, Division of Rheumatology, Department of Internal Medicine, Department of Medicine, School of Health Sciences, University of Ioannina, Greece

LANGUAGES: Greek (native), English

E-MAIL ADDRESS: fkarassa@uoi.gr

EDUCATION – POSTGRADUATE TRAINING

MEDICAL SCHOOL: University of Ioannina, Greece. Top admission rank (no. 2) in the School of Medicine, M.D. (1988)

- 1989-1990:** Compulsory medical primary care service in rural area according to regulations of the Greek National Health System, Doliana, Delvinaki, Ioannina, Greece
- 1990-1991:** General Practitioner, medical primary care service, Greek Social Security Agency, Ioannina, Greece
- 1991-1993:** Residency in Internal Medicine, Department of Internal Medicine, University Hospital of Ioannina, Medical School, University of Ioannina, Greece
- 1994-1998:** Residency in Rheumatology, Department of Pathophysiology, “Laikon” University Hospital of Athens, Medical School, University of Athens, Greece

CERTIFICATION AND LICENSURE

- 1988:** License to practice Medicine (Ioannina, Greece)
- 1998:** Specialty Board Certification, Greek Board of Rheumatology. According to the EU regulations after the end of my clinical training in Internal Medicine (2 years) and Rheumatology (4 years), I passed successfully the final national examinations, and I was qualified as *Rheumatologist* (Date of qualification: November 1998).

4. PhD THESIS

- 2000:** Department of Pathophysiology, Medical School, University of Athens, Greece (“*Systemic lupus erythematosus in Greece: clinical features, evolution and outcome. Neuropsychiatric lupus erythematosus: risk factors – prospective evaluation of predictors of magnetic resonance imaging evolution and*

clinical outcome”) – Grade: Excellent – Three (3) peer-reviewed publications in international medical journals were derived from my thesis.

POSTDOCTORAL RESEARCH

2000-2001: During this period, I worked at the Centre for Rheumatology (The Windeyer Institute of Medical Sciences, Centre for Rheumatology and Bloomsbury Rheumatology Unit, the Middlesex Hospital, Department of Medicine, University College London [UCL] Medical School, UK). UCL Medical School is ranked (<https://www.ucl.ac.uk/medical-school>) 6th in the world in the QS World University Rankings Top Medical Universities (2023). Also, the Centre for Rheumatology at UCL is one of the leading academic rheumatology units in the UK and it has been acknowledged as a Lupus Centre of Excellence (<https://www.ucl.ac.uk/rheumatology-bloomsbury/>). I was taught a wide variety of laboratory techniques including ELISA, cell culture, the development of B lymphocyte hybridomas from the peripheral blood of patients with systemic lupus erythematosus and antibody production, in order to define their contribution to disease pathology. I was also attending the lupus clinic and once a week the autoimmune rheumatic disease session.

2001-2005: I worked under Professor John P. A. Ioannidis as research fellow at the Department of Hygiene and Epidemiology, Department of Medicine, School of Health Sciences, University of Ioannina, Greece, seeking advanced training in epidemiology and biostatistics. During these years, I

organized and coordinated 5 international meta-analyses in the field of rheumatology (study design, writing of the research protocol, data collection, analysis of the results, and writing of the manuscript) with the contribution of many research groups. I also participated in a multicenter European study (“Genetic markers for osteoporosis”, the GENOMOS study), funded by the European Commission.

2007-2010: I worked under Professor John P. A. Ioannidis as research fellow at the Department of Hygiene and Epidemiology, Department of Medicine, School of Health Sciences, University of Ioannina, Greece. During 2008-2010, I participated in the international study “Genetics markers for osteoarthritis” (TREAT-OA project), funded by the European Commission. I also organized a systematic review on anti-TNF agents in immune-mediated diseases, awarded with a grant by the Greek Society of Rheumatology.

MAJOR ACADEMIC APPOINTMENTS

2004: Lecturer for the teaching of Pathophysiology and Internal Medicine, Department of Medicine, School of Health Sciences, University of Ioannina, Greece.

2005-2006: Lecturer of Rheumatology, Department of Internal Medicine, Medical School, University of Thessaly, Larisa, Greece.

2010-Present: Lecturer of Rheumatology, Department of Internal Medicine, Department of Medicine, School of Health Sciences, University of Ioannina, Greece.

ACADEMIC HONORS AND AWARDS

- 1982:** Honorary scholarship, State Scholarship Foundation for top admission rank (no. 2) in the Department of Medicine, School of Health Sciences, University of Ioannina, Greece.
- 1985:** Honorary annual scholarship, State Scholarship Foundation for being in the top 2% of the class of 1982, Department of Medicine, School of Health Sciences, University of Ioannina, Greece.
- 2000-2001:** Scholarship from the Greek Society of Rheumatology for postdoctoral training and research in the U.K.
- 2017:** Award for the best e-poster presentation at the 11th World Congress on Controversies in Neurology-Athens, Greece March 23-26, 2017 for the abstract entitled: «Coexistence of Multiple Sclerosis (MS) and Systemic Sclerosis (SSc): diagnostic and treatment considerations”.

TEACHING EXPERIENCE

- 1991-1993:** As trainee in Internal Medicine in the Academic Unit of Internal Medicine of Ioannina (Professor H. M. Moutsopoulos), Department of Medicine, I was involved in teaching medical history-taking and physical examination to the 3rd and 4th year medical students.
- 1994-1998:** As trainee in Rheumatology in the Department of Pathophysiology of Athens (Professor H. M. Moutsopoulos), Medical School, I was involved in teaching and supervising the 3rd and 4th year medical students.

- 1999-2005:** As research fellow at the Department of Hygiene and Epidemiology, Department of Medicine, School of Health Sciences, University of Ioannina, Greece, I was assigned teaching responsibilities.
- 2004:** As Lecturer at the Department of Medicine, School of Health Sciences, University of Ioannina, Greece, I was involved in teaching Pathophysiology and Internal Medicine (introduction to clinical diagnosis and differential diagnosis) to the 3rd and 6th year medical students, respectively.
- 2005-2006:** As Lecturer of Rheumatology at the Medical School, University of Thessaly, Larisa, I participated in teaching medical history-taking, physical examination, and differential diagnosis to the 3rd and 4th year medical students, as well as to trainee residents of Rheumatology, Division of Rheumatology, Department of Internal Medicine.
- 2007-2010:** As research fellow at the Department of Hygiene and Epidemiology, Department of Medicine, School of Health Sciences, University of Ioannina, Greece, I was assigned teaching responsibilities.
- 2010-Today:** As Lecturer of Rheumatology at the Department of Medicine, School of Health Sciences, University of Ioannina, Greece, I am involved in teaching pathophysiology and medical history-taking to the 3rd year medical students. In addition, I teach clinical/laboratory findings of autoimmune diseases and physical examination to the 4th year medical students as well as autoimmune diseases and rehabilitation to the 5th year medical students. I also teach common rheumatic diseases to the nurses of the University Hospital of Ioannina.

Speaker in Postgraduate Master Programs

2012, 2016: Reproductive Medicine, Head of the Master Program:
Professor D. Loutradis, University of Athens, School of
Medicine, Athens, Greece (“*Antiphospholipid Syndrome and
pregnancy*”, “*Systematic reviews and meta-analyses: basic
methodology and critical analysis*”)

CLINICAL EXPERIENCE

- During my training in Internal Medicine, I was involved in the management of various medical conditions in a wide spectrum of cases, which cut across all the subspecialties of Internal Medicine, acquiring considerable experience in the management of critically ill patients.
- During my training in Rheumatology, I was involved in the evaluation and management of in-patients presenting with signs and symptoms across the broad spectrum of clinical rheumatology, life-threatening autoimmune-disease manifestations and other illnesses associated with rheumatic syndromes. My clinical training also involved the outpatient-based clinic, where a large number of patients with various autoimmune diseases (rheumatoid arthritis, seronegative spondyloarthropathies, systemic lupus erythematosus, antiphospholipid syndrome, Sjogren’s syndrome, scleroderma, Raynaud’s phenomenon, mixed connective tissue disease, overlap syndromes, relapsing polychondritis, Behcet’s disease, autoimmune myopathies, vasculitides, and sarcoidosis) are followed. Patients with other musculoskeletal conditions, such as osteoarthritis, crystal-induced arthritis and bone/metabolic disorders or patients presenting with clinical features of rheumatologic conditions are also followed. Furthermore, I have gained skill in the special procedures of Rheumatology (joint aspiration and injection) and had the opportunity,

during my training in Rheumatology, to review indications for orthopedic surgery and orthopedic consultations in the rheumatic diseases, as well as the role of rehabilitation medicine in the management of rheumatic diseases. I participated 6 days a month at the hospital's acute medical services for Internal Medicine.

- From April 2000 to January 2001, I worked at the Centre for Rheumatology (The Windeyer Institute of Medical Sciences, Centre for Rheumatology, Bloomsbury Rheumatology Unit, the Middlesex Hospital, Department of Medicine, University College London Medical School, UK), principally in the research laboratory but also in the clinic of systemic autoimmune diseases. I also attended the academic meetings of the Department.
- From March 2005 to December 2006, I worked at the Rheumatology Division of University of Thessaly, Medical School, Larisa. I participated in the evaluation and management of outpatients (new and review) at the general rheumatology clinic, 4 days a week, while once a week I was responsible for patients' care with autoimmune diseases who were receiving intravenously immunosuppressive or biologic agents. I also provided consultation on in-patients with autoimmune diseases or diagnostic problems referring to rheumatology at the Department of Internal Medicine and all other Departments of the University Hospital of Larisa. I had General Medical on-call commitments 7 days a month.
- From June 2010 until today, I have been working at the Rheumatology Division of the Department of Medicine, School of Health Sciences, University of Ioannina, Greece. I participate in the evaluation and management of both new and return outpatients at the general rheumatology clinic 5 days a week. I also provide consultation on in-patients with autoimmune diseases or diagnostic problems referring to rheumatology at a number of Departments of the University Hospital of Ioannina. I am on-call for Rheumatology approximately 7 days a month.

COORDINATING EDITOR IN MEDICAL JOURNALS

2/2009-12/2019: Coordinating Editor of the ***European Journal of Clinical Investigation*** (Editor-in-Chief: Professor John P. A. Ioannidis). During these years: **1.** I contributed in attracting > 100 leading scientists as new members of the editorial committee of the journal **2.** I drafted new instructions to the authors for the journal, and **3.** I coordinated the efforts to attract to the journal reviews and original articles by leading scientists.

In addition, on a daily basis, I have been handling scientifically of approximately 1000 articles that we receive each year and I made decisions on which will be rejected immediately, which would be sent to members of the editorial board and to whom in particular, and which would go out to external peer-review. I was also in contact with the technical staff of the publishing house (Wiley) on issues relating to the release of each issue. Since 2009, I served as a reviewer of many scientific papers (153) in the field of rheumatology.

During these years, the journal's Impact Factor has been increased from **2.64** (2009) to **3.48** (2019) and its ranking was **34/165** (2019) among Journals of Internal and General Medicine.

MEMBER OF THE EDITORIAL BOARD IN 12 MEDICAL JOURNALS

REVIEWER IN MEDICAL JOURNALS

Peer-reviewer for >205 manuscripts in 15 medical journals since 2003.

ADDITIONAL QUALIFICATIONS

- Advanced level in computer use.
- Advanced level in Epidemiology learning through participation in the webinar entitled: “*Meta-analysis statistical models using R*”. The focus of this webinar was the interpretation and presentation of the results using meta-analysis including network meta-analysis. The CINeMA (confidence in network meta-analysis; <https://cinema.ispm.unibe.ch/>) software, a semiautomated assessment of the confidence in the results of network meta-analysis was explicitly presented. The methodological framework and the web application were also demonstrated.

RESEARCH INTERESTS – SCIENTIFIC CONTRIBUTIONS

Major Research Interests

- Systemic lupus erythematosus and particularly neuropsychiatric systemic lupus erythematosus
- Biologic treatments in the autoimmune diseases
- Evidence-based medicine and particularly meta-analyses related to controversial issues in the field of rheumatology

Brief presentation of publications, presentations and lectures

Peer-reviewed publications in international journals: 36

Authorship:

- 1st author: 21
- 2nd author: 5
- Last author: 5
- Other: 5

Total Impact Factor of Journals where papers have been published: 921.8

Mean Impact Factor of Journals where papers have been published: 25.6

Citations: 1.854 (according to ISI Web of Science-Citation Index, September 27th, 2024), **2.180** (according to SCOPUS-Citation Index, September 27th, 2024), **3.222** (according to Google Scholar September 27th, 2024)

H-index: 19 (ISI Web of Science and Scopus September 27th, 2024) **23** (Google Scholar September 27th, 2024)

Scientific publications in Greek Medical Journals: 5

Chapters in scientific books: 7

- International books: 3
- Greek books: 4

Oral/Poster Presentations: 23

- International Congresses: 14
- Greek Congresses: 9

Invited speaker: 37

- Greek Congresses-Meetings: 36
- International Congresses-Meetings: 1

Abstracts in Meetings: 13

- Abstracts in Greek Journals: 8
- Abstracts in International Journals: 5

Scientific / organizing committee of Greek meetings: 6

Scientific / organizing committee of International Meetings: 2

- Member of the Scientific Committee, 2007-2008 Multi-national 3E Initiative, Paris, France (formulation of evidence-based recommendations for the use of methotrexate in rheumatic disorders with the participation of 751 rheumatologists from 17 countries)
- Member of the Scientific Committee, 9th European Lupus Meeting

Session Chair in Greek Meetings: 2

Session Chair in International Meetings: 1

- XI Mediterranean Congress of Rheumatology, Heraklion, Crete, Greece, September 22-24, 2005

Research Grants

- 2003-2005:** I participated in the European study “Genetic markers for osteoporosis” (the GENOMOS study), funded by the European Commission (grant QLRT-2001-02629).
- 2005:** My project on the accuracy of anti-ribosomal P protein antibody testing for diagnosis of neuropsychiatric systemic lupus erythematosus (an international meta-analysis) was awarded a grant by the “Joseph and Esther Gani Foundation”, Ioannina, Greece.
- 2008-2010:** I participated in the international study “Genetic markers for osteoarthritis” (TREAT-OA project), funded by the European Commission (through Coordination Theme 1 [Health] of the European Union 7th Framework Program [grant HEALTH – F2-2008-00]).
- 2009:** My project on anti-TNF therapies in immune-mediated inflammatory diseases (a systematic review) was awarded a grant by the Greek Society of Rheumatology.

Publications in International Journals

1. Vlachoyiannopoulos PG, **Karassa FB**, Karakostas KX, Drosos AA, Moutsopoulos HM: Systemic Lupus Erythematosus in Greece. Clinical Features, Evolution and Outcome: a Descriptive Analysis of 292 Patients. *Lupus* 1993; 2: 303-12.
2. **Karassa FB**, Avdikou K, Pappas P, Nakopoulou L, Kostakis A, Boletis JN. Late renal transplant arterial thrombosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. *Nephrol Dial Transplant*. 1999; 14: 472-4.
3. **Karassa FB**, Ioannidis JP, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. *QJM* 2000; 93:169-74.
4. **Karassa FB**, Ioannidis JP, Boki KA, Touloumi G, Argyropoulou MI, Strigaris KA, Moutsopoulos HM. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. *Am J Med*. 2000; 109: 628-34.
5. **Karassa FB**, Isenberg DA. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. (Correspondence) *N Engl J Med*. 2001; 344: 382-3. [Erratum in: *N Engl J Med* 2001; 344: 1176].
6. Ioannidis JPA, **Karassa FB**. Bias in uncontrolled therapeutic trials in rheumatology due to selection of populations with extreme characteristics. *J Rheumatol*. 2001; 28: 1881-7.
7. Trikalinos TA, **Karassa FB**, Ioannidis JPA. Meta-analysis of the association between low-affinity Fcγ receptor gene polymorphisms and hematological and autoimmune diseases. *Blood* 2001; 98: 1634-5.

8. **Karassa FB**, Isenberg DA. Spontaneous rupture of the spleen: an unusual complication of systemic lupus erythematosus. *Lupus* 2001; 10: 873-5.
9. **Karassa FB**, Trikalinos TA, Ioannidis JPA and the FcγRIIa-SLE meta-analysis investigators. Role of the FcγRIIA polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. *Arthritis Rheum.* 2002; 46: 1563-71.
10. **Karassa FB**, Magliano M, Isenberg DA. Suicide attempts in patients with systemic lupus erythematosus. *Ann Rheum Dis.* 2003; 62: 58-60.
11. **Karassa FB**, Trikalinos TA, Ioannidis JPA and the FcγRIIIa-SLE meta-analysis investigators. The FcγRIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. *Kidney Int.* 2003; 63: 1475-82.
12. **Karassa FB**, Tatsioni A, Ioannidis JPA. Design, quality and bias in randomized controlled trials of systemic lupus erythematosus. *J Rheumatol.* 2003; 30: 979-84.
13. **Karassa FB**, Bijl M, Davies KA, Kallenberg CGM, Khamashta MA, Manger K, Michel M, Piette JC, Salmon JE, Song YW, Tsuchiya N, Yoo DH, Ioannidis JPA. The role of the FcγRIIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. *Arthritis Rheum.* 2003; 48: 1930-8.
14. **Karassa FB**, Trikalinos TA, Ioannidis JPA. The role of FcγRIIA and IIIA polymorphisms in autoimmune diseases. *Biomed Pharmacother.* 2004; 58: 286-91 (invited article).
15. Ioannidis JPA, Ralston SH, Bennett ST, Brandi ML, Grinberg D, **Karassa FB**, Langdahl B, van Meurs JBJ, Mosekilde L, Scollen S, Albagha OME, Bustamante M, Carey AH, Dunning AM, Enjuanes A, van Leeuwen JPTM,

- Mavilia C, Masi L, McGuigan FEA, Nogues X, Pols HAP, Reid DM, Schuit SCE, Sherlock RE, Uitterlinden AG for the GENOMOS Study. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. *JAMA* 2004; 292: 2105-14.
16. **Karassa FB**, Matsagas MI, Schmidt WA, Ioannidis JPA. Meta-Analysis: Test performance of ultrasonography for giant-cell arteritis. *Ann Intern Med*. 2005; 142: 359-69.
17. **Karassa FB**, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, Galeazzi M, Hirohata S, Hoffman IEA, Inanc M, Massardo L, Mathieu A, Mok CC, Morozzi G, Sanna G, Spindler AJ, Tzioufas AG, Yoshio T, Ioannidis JPA. Accuracy of anti-ribosomal P protein antibody testing for diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. *Arthritis Rheum*. 2006; 54: 312-24.
18. **Karassa FB**. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. (Correspondence) *N Engl J Med*. 2006; 354:764-5.
19. Raptopoulou A, Sidiropoulos P, Siakka P, Boki K, Drosos AA, Aslanidis S, Karras D, Pikazis D, Vassilopoulos D, **Karassa FB**, Boumpas DT. Evidence-based Recommendations for the Management of Ankylosing Spondylitis: Results of the Hellenic Working Group of the 3E Initiative in Rheumatology. *Clin Exp Rheumatol*. 2008; 26: 784-92.
20. **Karassa FB**, Ioannidis JPA. Mortality in systemic sclerosis. *Clin Exp Rheumatol*. 2008; 26(5 Suppl. 5): 85-93 (invited article).
21. Evangelou E, Chapman K, Meulenbelt I, **Karassa FB**, Loughlin J, Bos SD, Doherty M, Doherty S, Gomez-Reino JJ, Gonzalez A, Bjarni V, Halldorsson BV, Hauksson VB, Hofman A, Hart DJ, Ikegawa S, Ingvarsson T, Jiang Q, Jonsdottir I, Jonsson H, Kerkhof HJM, Lane NE, Li J, Lories RJ, van Meurs JBJ, Näkki A, Nevitt MC, Rodriguez-Lopez J, Shi D, Slagboom EP,

- Stefansson K, Tsezou A, Wallis GA, Watson C, Spector TD, Uitterlinden AG, Valdes AM, Ioannidis JPA. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. *Arthritis Rheum.* 2009; 60: 1710-21.
22. Ioannidis JPA, Tatsioni A, **Karassa FB**. A vision for the European Journal of Clinical Investigation: note from the new Editors. (Editorial) *Eur J Clin Invest.* 2010; 40: 1-3.
23. Ioannidis JPA, Tatsioni A, **Karassa FB**. Who is afraid of reviewers' comments? Or, why anything can be published and anything can be cited. (Editorial) *Eur J Clin Invest.* 2010; 40: 285-7.
24. Ioannidis JPA, Tatsioni A, **Karassa FB**. Published articles should not be dead and buried: introducing research updates. (Editorial) *Eur J Clin Invest.* 2010; 40:767-9.
25. Ioannidis JPA, **Karassa FB**. Agenda-wide issues in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. *BMJ.* 2010; 341: c4875. doi: 10.1136/bmj.c4875.
26. **Karassa FB**. Rituximab or Cyclophosphamide in ANCA-Associated Renal Vasculitis. (Correspondence) *N Engl J Med.* 2010; 363:2072-4.
27. Evangelou E, Valdes AM, Kerkhof HJM, Stykarsdottir U, Zhu YY, Meulenbelt I, Lories RJ, **Karassa FB**, Tylzanowski P, Bos SD, arcOGEN consortium, Akune T, Arden NK, Carr A, Chapman K, Cupples LA, Dai J, Deloukas P, Doherty M, Doherty S, Engstrom G, Gonzalez A, Halldorsson BV, Hammond CL, Hart DJ, Helgadottir H, Hofman A, Ikegawa S, Ingvarsson T, Jiang Q, Jonsson H, Kaprio J, Kawaguchi H, Kisand K, Kloppenburg M, Kujala UM, Lohmander LS, Loughlin J, Luyten FP, Mabuchi A, McCaskie A, Nakajima M, Nilsson PM, Nishida N, Ollier WER, Panoutsopoulou K, van de Putte T, Ralston SH, Rivadeneira F, Saarela J,

- Schulte-Merker S, Slagboom PE, Sudo A, Tamm A, Tamm A, Thorleifsson G, Thorsteinsdottir U, Tsezou A, Wallis GA, Wilkinson JM, Yoshimura N, Zeggini E, Zhai G, Zhang F, Jonsdottir I, Uitterlinden AG, Felson DT, van Meurs JB, Stefansson K, Ioannidis JPA, Spector TD. Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. *Ann Rheum Dis*. 2011; 70:349-55.
28. Ioannidis JPA, **Karassa FB**, Druyts E, Thorlund K, Mills EJ. Biologic agents in rheumatology: unmet issues after 200 trials and \$200 billion sales. *Nat Rev Rheumatol*. 2013; 9(11):665-73.
29. **Karassa FB**. Induction Regimens for ANCA-Associated Vasculitis. (Correspondence) *N Engl J Med*. 2013; 369(19): 1864-5.
30. **Karassa FB**, Ioannidis JPA. A transparent future for clinical trial reporting. *Nat Rev Rheumatol*. 2015; 11(6): 324-5.
31. Tatsioni A, **Karassa FB**, Goodman SN, Zarin DA, Fanelli D, Ioannidis JPA. Lost evidence from registered large long-unpublished randomized controlled trials: a survey. *Ann Intern Med*. 2019; 171: 300-1.
32. Zarkavelis G, Mauri D, **Karassa FB**, Kampletsas E, Pentheroudakis G, Pappadaki A, Mavroeidis L, Ntellas P, Gkoura S, and Gazouli I. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. *Contemporary Oncology / Wspolczesna Onkologia*. 2020; 24:75-8.
33. **Karassa FB**. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. (Correspondence) *N Engl J Med*. 2020; 382: e38 (published online).

34. **Karassa FB**, Bougioukas KI, Pelechas E, Skalkou A, Argyriou E, Haidich AB. Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses. *PLoS One*. 2022; 17: e0272327.
35. **Karassa FB**, Pelechas E, Zouzos G. The immunogenetics of Vasculitis. *Adv Exp Med Biol*. 2022; 1367: 299-334.
36. Zarachi A, Pelechas E, Tsikou A, Kalambokis GN, Zioga A, Panteli KE, Rapti I, Filippas-Ntekouan S, Kastanioudakis I, **Karassa FB**. Immune-mediated inner ear disease associated with type 1 autoimmune hepatitis: a challenging coexistence. *Mediterr J Rheumatol*. 2022; 33: 349-60.

Chapters in International Scientific Books

1. **Karassa FB**, Ioannidis JPA. Influenza: vaccination and treatment. In: Gibson PG (ed.), *Evidence-based Respiratory Medicine*, BMJ books, Blackwell Publishing Ltd, Oxford, UK, 2005, chapter 4.4 pp. 335-47.
2. Katsanos AH, Kyriakidi K, **Karassa FB**, Politis D, Skamnelos A, Christodoulou DK, Katsanos KH. Biomarker Development in Chronic Inflammatory Diseases. Sections: C. Rheumatology. Biomarker of Chronic Autoimmune Rheumatic Diseases. In: D' Hooghe TM (ed.), *Biomarkers for Endometriosis*. Publisher: Springer, 233 Spring Street/ New York, NY 10013/USA, 2017, chapter page 41 pp.61-75.
3. **Karassa FB**, Pelechas E, Zouzos G. The Immunogenetics of Vasculitis. In: Rezaei N, Rajabi F (eds), *The Immunogenetics of Dermatologic Diseases*. *Adv Exp Med Biol*. Publisher: Springer, 233 Spring Street/ New York, NY 10013/USA 2022; vol 1367, chapter page 299 pp. 299-334.